中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝脏免疫炎症在非酒精性脂肪性肝病发生发展中的作用

祝娟娟 程明亮 赵雪珂

引用本文:
Citation:

肝脏免疫炎症在非酒精性脂肪性肝病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2016.03.038
基金项目: 

国家自然科学基金(81560100); 

详细信息
  • 中图分类号: R575.5

Role of liver immunological inflammation in development and progression of nonalcoholic fatty liver disease

Research funding: 

 

  • 摘要:

    非酒精性脂肪性肝病(NAFLD)是临床上常见的肝脏疾病之一,其发病机制较为复杂,"二、三次打击"学说仍是目前得到公认的NAFLD的主要发病机制。但近年来,肝脏免疫炎症在NAFLD的发生、发展中逐步得到众多研究者的重视。从肝脏免疫炎症的角度,阐述了肝脏免疫炎症导致NAFLD发生、发展的机制。

     

  • [1]LOOMBA R,SANYAL AJ.The global NAFLD epidemic[J].Nat Rev Gastroenterol Hepatol,2013,10(11):686-690.
    [2]YEH MM,BRUNT EM.Pathological features of fatty liver disease[J].Gastroenterology,2014,147(4):754-764.
    [3]de MINICIS S,DAY C,SVEGLIATI-BARONI G.From NAFLD to NASH and HCC:pathogenetic mechanisms and therapeutic insights[J].Curr Pharm Des,2013,19(29):5239-5249.
    [4]DOWMAN JK,TOMLINSON JW,NEWSOME PN.Systematic review:the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther,2011,33(5):525-540.
    [5]AHMED M.Non-alcoholic fatty liver disease in 2015[J].World J Hepatol,2015,7(11):1450-1459.
    [6]ONIKI K,SARUWATARI J,IZUKA T,et al.Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects[J].PLo S One,2015,10(7):132640.
    [7]DIXON LJ,BARNES M,TANG H,et al.Kupffer cells in the liver[J].Compr Physiol,2013,3(2):785-797.
    [8]LESTER SN,LI K.Toll-like receptors in antiviral innate immunity[J].J Mol Biol,2014,426(6):1246-1264.
    [9]AVBELJ M,WOLZ OO,FEKONJA O,et al.Activation ol lymphoma-associated My D88 mutations via allostery induced TIR-domain oligomerization[J].Blood,2014,124(26):3896-3904.
    [10]WANG H,LAFDIL F,KONG X,et al.Signal transducer and activator of transcription 3 in liver diseases:a novel therapeutic target[J].Int J Biol,2011,7(5):536-550.
    [11]BIEGHS V,TRAUTWEIN C.Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease[J].Hepatobiliary Surg Nutr,2014,3(6):377-385.
    [12]MEDVEDEV AE.Toll-like receptor polymorphisms,inflammatory and infectious diseases,allergies,and cancer[J].J Interferon Cytokine Res,2013,33(9):467-484.
    [13]RAMADORI P,KROY D,STREETZ KL.Immunoregulation by lipids during the development of non-alcoholic steatohepatitis[J].Hepatobiliary Surg Nutr,2015,4(1):11-23.
    [14]LIU M,GUO S,HIBBERT JM,et al.CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications[J].Cytokine Growth Factor Rev,2011,22(3):121-130.
    [15]IYER SS,CHENG G.Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease[J].Crit Rev Immunol,2012,32(1):23-63.
    [16]ZHANG X,SHEN J,MAN K,et al.CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of nonalcoholic steatohepatitis[J].J Hepatol,2014,61(6):1365-1375.
    [17]SABAT R,GRTZ G,WARSZAWSKA K,et al.Biology of interleukin-10[J].Cytokine Growth Factor Rev,2010,21(5):331-344.
    [18]RYAN JJ,KASHYAP M,BAILEY D,et al.Mast cell bomeostasis:a fundamental aspect of allergic disease[J].Crit Rev Immunol,2007,27(1):15-32.
    [19]GU QP,BAI AP.Interleukin-10 and inflammatory bowel disease[J].World Chin J Dig,2011,19(1):57-61.(in Chinese)顾秋萍,白爱平.白介素-10与炎症性肠病[J].世界华人消化杂志,2011,19(1):57-61.
    [20]QING Q,ZHOU DS.The variation and significance of serum ratio of IL-18 and IL-10 in NAFLD rats[J].Acta Univ Med Anhui,2013,48(9):1041-1043.(in Chinese)秦清,周冬生.非酒精性脂肪性肝病大鼠血清白介素18、白介素10及其比值的变化和意义[J].安徽医科大学学报,2013,48(9):1041-1043.
    [21]HOLAN V,ZAJICOVA A,JAVORKOVA E,et al.Distinct cytokines balance the development of regulatory T cells and interleukin-10-producing regulatory B cells[J].Immunology,2014,141(4):577-586.
    [22]KONG X,FENG D,MATHEWS S,et al.Hepatoprotective and antifibrotic functions of interleukin-22:therapeutic potential for the treatment of alcoholic liver disease[J].J Gastroenterol Hepatol,2013,28(Suppl 1):56-60.
    [23]GAO B,JEONG WI,TIAN Z.Liver:an organ with predominant innate immumity[J].Hepotology,2008,47(2):729-736.
    [24]GAO B,RADAEVA S,PARK O.Liver natural killer and natural killer T cells:immunobiology and emerging roles in liver diseases[J].J Leukoc Biol,86(3):513-528.
    [25]ADLER M,TAYLOR S,CKEBUGEU K,et al.Intrahepatic natural killer T cell populations are increased in human hepatic steatosis[J].World J Gastroenterol,2011,17(13):1725-1731.
    [26]MAHER JJ,LEON P,RYAN JC.Beyond insulin resistance:innate immunity in non-alcoholic steatohepatitis[J].Hepatology,2008,48(2):670-678.
    [27]ELINAV E,PAPPO O,SKLAIR-LEVY M,et al.Amelioration of non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels[J].J Pathol,2006,208(1):74-81.
    [28]TANG T,SUI Y,LIAN M,et al.Pro-Inflammatory activated Kupffer cells by lipids induce hepatic NKT cells deficiency through activation-Induced cell death[J].PLo S One,2013,8(12):81949.
    [29]COOL N,PONSAERTS P,van TENDELOO VF,et al.Regulatory T cells and human disease[J].Clin Dev Immunol,2007:89195.
    [30]ROBERTSON FC,BERZOFSKY JA,TERABE M.NKT cell networks in the regulation of tumor immunity[J].Front Immunol,2014,5:543.
    [31]GUO Y,LI W,YE AZ,et al.Study on chemotaxis of regulatory T cells induced by different antigents in mice[J].Chin J Immunol,2015,31(8):1032-1036.(in Chinese)郭音,李伟,叶艾竹,等.不同抗原诱导后小鼠调节性T淋巴细胞趋化特性动态研究[J].中国免疫学杂志,2015,31(8):1032-1036.
    [32]VONGHIA L,MICHIELSEN P,FRANCQUE S.Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis[J].Int J Mol Sci,2013,14(10):19867-19890.
    [33]CIPOLLETTA D,FEUERER M,LI A,et al.PPAR-γis a major driver of the accumulation and phenotype of adipose tissue Treg cells[J].Nature,2012,486(7404):549-553.
    [34]ILAN Y.Immune therapy for non-alcoholic steatohepatitis:are we there yet?[J].J Clin Gastroenterol,2013,47(4):298-307.
    [35]ZHOU LL.The expression of Th 17 related with cytokine in NAFLD[D].Fujian Med Univ,2014.(in Chinese).周丽丽.Th17细胞及相关细胞因子在非酒精性脂肪肝模型中的表达[D].福建医科大学,2014.
    [36]SUTTI S,JINDAL A,LOCATELLI I,et al.Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH[J].Hepatology,2014,59(3):886-897.
    [37]TANG Y,BIAN Z,ZHAO L,et al.Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease[J].Clin Exp Immunol,2011,166(2):281-290.
    [38]MARINONI B,CERIBELLI A,MASSAROTTI MS,et al.The Th17 axis in poriatic disease:pathogenetic and therapeutic implications[J].Auto Immun Highlights,5(1):9-19.
  • 加载中
计量
  • 文章访问数:  1481
  • HTML全文浏览量:  35
  • PDF下载量:  414
  • 被引次数: 0
出版历程
  • 出版日期:  2016-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回